dual glp 1 and gip receptor agonist examples Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Dual GLP-1/GIP receptor agonists mechanism

While the most pronounced weight loss with GLP-1RA therapy tends to occur within the first 6 months of treatment, continued use is generally associated with maintenance or further incremental weight loss

Compounded medications use the same active ingredients as brand-name versions, prepared by FDA-registered compounding pharmacies following strict quality standards

For selected patients, yes

Future Directions and Research Priorities Emerging Therapeutic Approaches Triple agonist retatrutide and combinations including cagrisema have progressed to phase 3 trials as obesity treatments with early data suggesting even greater weight loss than tirzepatide [83]

Lancet 368(9548):16961705 Muskiet MHA, Tonneijck L, Smits MM, Van Baar MJB, Kramer MHH, Hoorn EJ et al (2017) GLP-1 and the kidney: From physiology to pharmacology and outcomes in diabetes

Researchers said this suggested that the underlying diabetes rather than the medication may be the causal factor.